NASDAQ:MRSN Mersana Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mersana Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.85 -1.01 (-4.84 %) (As of 09/23/2020 12:50 PM ET) Add Compare Share Today's Range$19.68Now: $19.85▼$21.0150-Day Range$16.20MA: $19.25▼$25.7052-Week Range$1.32Now: $19.85▼$26.64Volume20,994 shsAverage Volume1.27 million shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/ABeta2.47 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.75, Mersana Therapeutics has a forecasted upside of 19.4% from its current price of $20.72.Amount of Analyst CoverageMersana Therapeutics has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMersana Therapeutics has received 222 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMersana Therapeutics has received 194 “underperform” votes. (Add your “underperform” vote.)Community SentimentMersana Therapeutics has received 53.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote “Outperform” if you believe MRSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $851,540.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Mersana Therapeutics is held by insiders.Percentage Held by Institutions95.74% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to decrease in the coming year, from ($1.30) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -15.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -15.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 12.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.24 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRSN Previous Symbol CUSIPN/A CIK1442836 Webwww.mersana.com Phone617-498-0020Debt Debt-to-Equity Ratio0.05 Current Ratio13.15 Quick Ratio13.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.12 million Price / Sales32.24 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book12.10Profitability EPS (Most Recent Fiscal Year)($0.65) Net Income$-28,210,000.00 Net Margins-4,119.91% Return on Equity-54.92% Return on Assets-43.90%Miscellaneous Employees86 Outstanding Shares68,415,000Market Cap$1.36 billion Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $19.85 -1.01 (-4.84 %) (As of 09/23/2020 12:50 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MRSN News and Ratings via Email Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions How has Mersana Therapeutics' stock been impacted by Coronavirus? Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRSN shares have increased by 207.3% and is now trading at $19.85. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Mersana Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mersana Therapeutics. When is Mersana Therapeutics' next earnings date? Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Mersana Therapeutics. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics Inc (NASDAQ:MRSN) posted its quarterly earnings data on Friday, August, 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.03. The business had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.43 million. Mersana Therapeutics had a negative return on equity of 54.92% and a negative net margin of 4,119.91%. View Mersana Therapeutics' earnings history. What price target have analysts set for MRSN? 5 brokers have issued 12-month target prices for Mersana Therapeutics' shares. Their forecasts range from $20.00 to $32.00. On average, they anticipate Mersana Therapeutics' stock price to reach $24.75 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price. View analysts' price targets for Mersana Therapeutics. Are investors shorting Mersana Therapeutics? Mersana Therapeutics saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 5,840,000 shares, an increase of 20.9% from the July 30th total of 4,830,000 shares. Based on an average trading volume of 1,860,000 shares, the short-interest ratio is presently 3.1 days. View Mersana Therapeutics' Short Interest. Who are some of Mersana Therapeutics' key competitors? Some companies that are related to Mersana Therapeutics include Bausch Health Companies (BHC), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), MorphoSys (MOR), Arena Pharmaceuticals (ARNA), Evotec (EVTCY), FibroGen (FGEN), Allakos (ALLK) and Legend Biotech (LEGN). View all competitors. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), Dynavax Technologies (DVAX), Marvell Technology Group (MRVL), Inovio Pharmaceuticals (INO), Novavax (NVAX), Vertex Pharmaceuticals (VRTX) and Docusign (DOCU). Who are Mersana Therapeutics' key executives? Mersana Therapeutics' management team includes the following people: Ms. Anna Protopapas, Pres, CEO & Director (Age 55)Mr. David A. Spellman, Chief Financial Officer (Age 42)Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)Mr. Mikhail Papisov Ph.D., Co-FounderMs. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications When did Mersana Therapeutics IPO? (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Mersana Therapeutics' stock symbol? Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN." Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (11.89%), Vanguard Group Inc. (4.19%), Orbimed Advisors LLC (2.79%), Avidity Partners Management LP (1.56%), FMR LLC (1.56%) and FMR LLC (1.56%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Ashish Mandelia, Enterprise Associates 14 New, Eva M Jack, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger. View institutional ownership trends for Mersana Therapeutics. Which institutional investors are selling Mersana Therapeutics stock? MRSN stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Sofinnova Investments Inc., Russell Investments Group Ltd., Quantitative Systematic Strategies LLC, UBS Group AG, and Algert Global LLC. Company insiders that have sold Mersana Therapeutics company stock in the last year include Ashish Mandelia, Eva M Jack, and Scott D Sandell. View insider buying and selling activity for Mersana Therapeutics. Which institutional investors are buying Mersana Therapeutics stock? MRSN stock was purchased by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Vanguard Group Inc., FMR LLC, FMR LLC, Artal Group S.A., Marshall Wace North America L.P., Candriam Luxembourg S.C.A., and Orbimed Advisors LLC. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, Enterprise Associates 14 New, and Lawrence M Alleva. View insider buying and selling activity for Mersana Therapeutics. How do I buy shares of Mersana Therapeutics? Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mersana Therapeutics' stock price today? One share of MRSN stock can currently be purchased for approximately $19.85. How big of a company is Mersana Therapeutics? Mersana Therapeutics has a market capitalization of $1.36 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe. What is Mersana Therapeutics' official website? The official website for Mersana Therapeutics is www.mersana.com. How can I contact Mersana Therapeutics? Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
